Loading
Cheap old drugs such as aspirin, statins, metformin and beta-blockers show hints of cancer benefit but no company will pay for the trials. Create a public fund and a way to update their labels.
Repurposing candidates with plausible mechanisms and observational signals rarely reach definitive trials because generic status removes the commercial incentive; the aspirin adjuvant trials (ADD-ASPIRIN) are a rare exception. The proposal is a dedicated public fund for pragmatic, registry-embedded randomised trials of generics in defined cancer indications, coupled with a regulatory pathway allowing third parties (academic groups, health systems) to obtain label updates, and payer commitments to reimburse on positive results.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, Cancer Research UK.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.